Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Dual-Targeting PSMA And FRα Drug Conjugate Advances to U.S. Trial for Prostate Cancer June 18, 2026
- Phase 1 RIALTO Trial: Radiotherapy for Metastatic Prostate Cancer With Incomplete Hormone Response June 18, 2026
- Decipher Genomic Classifier Identifies Patients Who Benefit from Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer June 18, 2026
- CRISPR Advances June 16, 2026

Overcoming Resistance in Metastatic Prostate Cancer: Repurposing Pimitespib
/in Drug repurposing, Preclinical Research/by MaxBA1106 Antibody Shows Promise in Early Trials In Solid Tumors
/in Clinical Trial, Not PCa related/by MaxQ702 Drug Shows Promise in Early Trials: Could Be Useful Against Prostate Cancer
/in Clinical Trial, Not PCa related/by MaxNezastomig (REGN5678): New Drug Combo Shows Promise In mCRPC, But Safety Is A Concern
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Potential Treatment For Early Prostate Cancer: TGW101
/in Clinical Trial, Non-Metastatic, Not PCa related, Phase 1/by MaxOrally Delivered CRISPR Therapy, Groundbreaking Evolution
/in CRISPR, Not PCa related, Preclinical Research/by Max225Ac-Macropa-PEG4-YS5: a CD46-Targeted 225Ac Therapy for Prostate Cancer
/in Preclinical Research/by MaxNext-Generation ADCs for Cancer Treatment with Potential in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by Max